Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN

User menu

  • Subscribe
  • My alerts
  • My Cart
  • Log in

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JPN
  • Subscribe
  • My alerts
  • My Cart
  • Log in
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Med Life with Dr. Horton
    • Podcasts
    • Videos
    • Alerts
    • RSS
    • Classified ads
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Activate online account
    • Look up login
    • Earn CPD Credits
    • Members Corner
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
    • Activate subscription
    • Look up login
    • Manage account
    • Manage IPs
    • View Reports
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Loperamide abuse

Tony Antoniou and David N. Juurlink
CMAJ June 12, 2017 189 (23) E803; DOI: https://doi.org/10.1503/cmaj.161421
Tony Antoniou
Department of Family and Community Medicine, St. Michael’s Hospital, and Department of Family and Community Medicine, University of Toronto (Antoniou); Institute for Clinical Evaluative Sciences, and Department of Medicine, Sunnybrook Health Sciences Centre (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tantoniou@smh.ca
David N. Juurlink
Department of Family and Community Medicine, St. Michael’s Hospital, and Department of Family and Community Medicine, University of Toronto (Antoniou); Institute for Clinical Evaluative Sciences, and Department of Medicine, Sunnybrook Health Sciences Centre (Juurlink), Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Loperamide is not just an innocuous antidiarrheal agent

At therapeutic doses (16 mg or less per day), loperamide is an opioid with psychoactive effects that are limited by poor absorption when taken orally and active efflux from the central nervous system by the membrane transporter P-glycoprotein.1,2 Recreational use of loperamide for its euphoric properities or to lessen symptoms of opioid withdrawal involves large oral dosages (more than 70 mg per day) with or without intentional ingestion of P-glycoprotein inhibitors such as quinine.1 Because of its opioid effects, nonprescription status and low cost, loperamide is sometimes referred to as “poor man’s methadone.”1

Abuse of loperamide is increasing

Of 179 cases of loperamide abuse reported to the United States National Poison Data System between 2008 and 2016, about half were reported after 2014; 137 (77%) involved men and the median age was 26 years.3

Patients may present with cardiac manifestations without overt opioid toxicity

In addition to possible depression of respiratory and central nervous systems, supratherapeutic concentrations of loperamide have been associated with QTc prolongation, QRS widening, ventricular dysrhythmias, syncope and sudden death.3–5

Diagnosis of loperamide abuse requires a high index of suspicion

Loperamide is not detected by routine drug screens. Typically, a patient with loperamide abuse will have a history of opioid misuse or recent discontinuation of prescription opioids and will present with unexplained syncope and electrocardiogram abnormalities .1,4,5

Treatment is mostly supportive

Supportive care is the mainstay of treatment.4 Naloxone has been used to reverse coma and respiratory depression.4 Optimal management of cardiac toxicity is unknown. Torsades de pointes should be treated with standard therapy, including magnesium and overdrive pacing.4,5 Sodium bicarbonate has been used for loperamide-related QRS widening, but its utility is unclear.4,5

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Stanciu CN,
    2. Gnanasegaram SA
    . Loperamide, the “poor man’s methadone”: brief review. J Psychoactive Drugs 2017;49:18–21.
    OpenUrl
  2. ↵
    1. Sadeque AJ,
    2. Wandel C,
    3. He H,
    4. et al
    . Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68:231–7.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Eggleston W,
    2. Marraffa JM,
    3. Stork CM,
    4. et al
    . Notes from the field: cardiac dysrhythmias after loperamide abuse — New York, 2008–2016. MMWR Morb Mortal Wkly Rep 2016;65:1276–7.
    OpenUrl
  4. ↵
    1. Eggleston W,
    2. Clark KH,
    3. Marraffa JM
    . Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med 2017; 69:83–6.
    OpenUrl
  5. ↵
    1. Marraffa JM,
    2. Holland MG,
    3. Sullivan RW,
    4. et al
    . Cardiac conduction disturbance after loperamide abuse. Clin Toxicol (Phila) 2014; 52:952–7.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (23)
CMAJ
Vol. 189, Issue 23
12 Jun 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Loperamide abuse
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
Citation Tools
Loperamide abuse
Tony Antoniou, David N. Juurlink
CMAJ Jun 2017, 189 (23) E803; DOI: 10.1503/cmaj.161421

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Loperamide abuse
Tony Antoniou, David N. Juurlink
CMAJ Jun 2017, 189 (23) E803; DOI: 10.1503/cmaj.161421
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Loperamide is not just an innocuous antidiarrheal agent
    • Abuse of loperamide is increasing
    • Patients may present with cardiac manifestations without overt opioid toxicity
    • Diagnosis of loperamide abuse requires a high index of suspicion
    • Treatment is mostly supportive
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Scopus
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Scopus (1)
  • Google Scholar

More in this TOC Section

  • Zollinger–Ellison syndrome
  • Benign splenic regrowth mistaken as recurrent renal cell carcinoma
  • Plastic bronchitis in a 3-year-old boy
Show more Practice

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Videos
  • Alerts
  • RSS

Information for

  • Advertisers
  • Authors
  • CMA Members
  • Copyright and Permissions
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact

Copyright 2019, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire